Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Matej Djordjevic

M.D., Ph.D. Cand.


Clinical Researcher

I am a study doctor in the Wellcome-funded Function and Cognition in Early Psychosis (FOCUS) trial, led by Dr Robert McCutcheon, which investigates the effects of xanomeline-trospium compared with standard antipsychotics on cognition in schizophrenia spectrum disorders. I hold a medical degree from the University of Groningen (NL), where I also completed my doctoral research on psychosocial factors in early-phase psychotic disorders. I have experience working with Ecological Momentary Assessment (EMA) data and in cross-cultural psychiatric epidemiology. I am committed to the generation of rigorous evidence that improves both the prevention of psychotic disorders and the quality of care for those affected by them.